Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer
Authors:
- 15 September 2016
- journal article
- research article
- Published by Springer Nature in Tumor Biology
- Vol. 37 (11) , 14765-14772
Abstract
Epithelial ovarian cancer (EOC) remains the deadliest form of gynecological cancers. Optimal tumor debulking, no matter the primary or the interval, is the most important prognostic factor for EOC, so there is an urgent demand for biomarkers to predict surgical outcome. The aim of this study was to investigate whether serum human epididymis protein 4 (HE4) and cancer antigen 125 (CA125) could predict surgical outcome of EOC. The levels of preoperative serum HE4 and CA125 were determined by electrochemiluminescence (ECLIA) in 82 EOC patients, comprising 39 subjected to primary debulking surgery (PDS) and 43 with extensive stage III or IV disease to neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS). Among 39 patients subjected to primary debulking surgery, HE4 was superior to CA125 in predicting surgical outcome (area under curve [AUC] 0.758 vs. 0.633). At a cutoff of 353.22 pmol/L, HE4 reached 77.4 % in sensitivity and 75 % in specificity. The prediction of surgical outcome of interval debulking surgery based on preoperative HE4 and CA125 values was performed in 43 patients who received NACT-IDS. The difference of AUC between HE4 and CA125 (0.793 vs. 0.663) indicating that HE4 was the better biomarker to predict surgical outcome of IDS. A pre-IDS HE4 value of 154.3 pmol/L is the optimal cutoff to identify patients who would not benefit from IDS with a sensitivity of 92.9 % and a specificity of 69 %. The change (>70 %) of HE4 before and after neoadjuvant chemotherapy could predict optimal interval debulking surgery. Serum HE4 was superior to CA125 in predicting surgical outcome of primary debulking surgery and interval debulking surgery. The change (absolute value or percentage) of HE4 in neoadjuvant chemotherapy could predict the outcome of interval debulking surgery.Keywords
Funding Information
- Guilin research and technology development project (20150126-4-4)
This publication has 35 references indexed in Scilit:
- Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancerEuropean Journal of Cancer, 2011
- Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancerGynecologic Oncology, 2011
- Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancerJournal of Cancer Research and Clinical Oncology, 2011
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian CancerNew England Journal of Medicine, 2010
- The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinomaArchives of Gynecology and Obstetrics, 2010
- Residual Cancer Stem Cells after Interval Cytoreductive Surgery following Neoadjuvant Chemotherapy Could Result in Poor Treatment Outcomes for Ovarian CancerOnkologie, 2010
- Preoperative serum CA‐125 levels and risk of suboptimal cytoreduction in ovarian cancer: A meta‐analysisJournal of Surgical Oncology, 2009
- Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trialBritish Journal of Cancer, 2009
- Multi-Institutional Reciprocal Validation Study of Computed Tomography Predictors of Suboptimal Primary Cytoreduction in Patients With Advanced Ovarian CancerJournal of Clinical Oncology, 2007
- Human Epididymis Protein 4 (HE4) Is a Secreted Glycoprotein that Is Overexpressed by Serous and Endometrioid Ovarian CarcinomasCancer Research, 2005